CYTK

Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

Wall Street analysts forecast CYTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTK is 81.50 USD with a low forecast of 61.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cytokinetics Inc revenue for the last quarter amounts to 1.94M USD, increased 318.14 % YoY.

Cytokinetics Inc. EPS for the last quarter amounts to -2.55 USD, increased 87.50 % YoY.

Cytokinetics Inc (CYTK) has 498 emplpoyees as of December 16 2025.

Today CYTK has the market capitalization of 7.60B USD.